PubMed دسترسی آزاد

[Diagnostics and treatment of hepatocellular carcinoma and biliary carcinomas-Living guidelines].

استودیوی صوتی مقاله

پخش حرفه‌ای فارسی و انگلیسی

در حال بررسی نسخه‌های صوتی ذخیره‌شده…

صوت تولیدشده با هوش مصنوعی است. برای کاربرد علمی یا درمانی، متن و منبع اصلی را بررسی کنید.
خواندن هوشمند فارسی و انگلیسی در حال آماده‌سازی صداهای مرورگر…
تنظیم صدای طبیعی و سرعت

صداهایی که در نامشان «Natural»، «Neural» یا «Online» دیده می‌شود معمولاً طبیعی‌ترند. انتخاب صدا به صداهای نصب‌شده در ویندوز و مرورگر شما بستگی دارد.

چکیده اصلی

The S3 guidelines "Diagnostics and treatment of hepatocellular carcinoma and biliary carcinomas" (version 5.2, June 2025) are conceived as living guidelines and are regularly updated. They represent an evidence-based foundation for the interdisciplinary care and integrate current developments in diagnostics, imaging and treatment.For HCC, treatment is guided by the BCLC stage, liver function, and the patient's general condition. In early-stage disease, liver resection, liver transplantation, and local ablative therapies represent potentially curative treatment options, whereas interventional and modern systemic therapies are used in more advanced stages. For biliary carcinomas, assessment of resectability is of particular importance, as R0 resection represents the only curative treatment option. In advanced disease, modern immunotherapies, molecular characterization, and targeted therapies have become increasingly important.

متن کامل اصلی

نسخه دارای مجوز در منبع علمی در دسترس است.

لینک مستقیم از metadata منبع گرفته شده و در تب جدید باز می‌شود.

باز کردن متن کامل

کلیدواژه‌ها

BCLC criteriaImmunotherapyLiver surgeryMolecular profilingTargeted therapy
در همین زیرشاخه

مقاله‌های مرتبط

PubMed2026

ATI-2341 TFA promotes acquisition of epithelial-like immunophenotype in bone marrow mesenchymal stem cells and alleviates intrauterine adhesion in a rat model.

BACKGROUND: Intrauterine adhesion (IUA) is a common complication of endometrial injury. Bone marrow mesenchymal stem cells (BMSCs) have been implicated in endometrial repair, but strategies to enhance their therapeutic efficacy remain to be optimized. The C-X-C chemokine receptor type 4 (CXCR4)/C-X-C motif chemokine ligand 12 (CXCL12) axis plays a pivotal role in BMSC homing. OBJECTIVE: This study aimed to test the hypothesis that ATI-…

PubMed2026

Corrigendum to: Bone marrow mesenchymal stem cells relieve rheumatoid arthritis by blocking JAK/STAT and TLR-4/NF-?B pathways.

The authors have informed the Pakistan Journal of Pharmaceutical Sciences (PJPS) of an error in Figure 5 of the published article. During the editorial revision process, an incorrect version of Figure 5 was inadvertently included in the final published version. The authors have confirmed that the extreme-right panel (panel D) should be removed and that the remaining panels constitute the corrected Figure 5. Accordingly, Figure 5 is cor…

PubMed2026

Better to Be Lucky Than Good: How Clinicians and Patients Frame Medical Outcomes.

Notions of good or bad luck sit uncomfortably in contemporary medical practice defined by efforts to control life through biomedical knowledge and skilled expertise. Yet, talk about luck is common in healthcare to explain medical courses of action. Framing medical results as fortunate or unfortunate bridges the gap between predicted probabilities and variation in individual cases without undermining scientific neutrality. Luck mediates…

PubMed2026

Bone marrow mesenchymal stem cells relieve rheumatoid arthritis by blocking JAK/STAT and TLR-4/NF-κB pathways.

BACKGROUND: Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by synovial inflammation and joint destruction. Bone marrow mesenchymal stem cells (BMSCs) have shown therapeutic potential in RA, but the underlying mechanisms remain poorly understood. OBJECTIVES: To investigate the effects of BMSCs on human RA fibroblast-like synovial MH7A cells and complete Freund's adjuvant (CFA)-induced arthritis in rats and to e…